ストックスクリーナーアプリを入手
7.245
0.47%
-0.125
前日終値:
$7.37
開ける：
$7.09
24時間の取引高:
446.24K
Relative Volume:
5.87
時価総額：
$6.01M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-2.07%
1か月 パフォーマンス:
+0.00%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$7.09
$7.61
1週間の範囲:
$6.71
$7.6437
52週間の値動き範囲:
$6.71
$13.47
Jade Biosciences Inc Stock (JBIO) Company Profile
JBIO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
JBIO
Jade Biosciences Inc
|
7.245 | 248.70M | 0 | 0 | 0 | 0.00 |
|
ONC
Beigene Ltd Adr
|
240.00 | 25.61B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
446.04 | 114.83B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.29 | 41.82M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.11 | 66.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
73.64 | 6.36B | 0 | -153.72M | -103.81M | -2.00 |
Jade Biosciences Inc Stock (JBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-07 | 開始されました | Wedbush | Outperform |
| 2025-05-05 | 開始されました | Stifel | Buy |
| 2025-05-02 | 開始されました | TD Cowen | Buy |
| 2024-06-18 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-06-18 | ダウングレード | TD Cowen | Buy → Hold |
| 2024-06-18 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-06-17 | ダウングレード | BTIG Research | Buy → Neutral |
| 2024-06-17 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-06-17 | ダウングレード | Wedbush | Outperform → Neutral |
| 2024-03-25 | 再開されました | Jefferies | Buy |
| 2023-12-08 | 開始されました | Wells Fargo | Equal Weight |
| 2023-03-01 | 開始されました | Guggenheim | Buy |
| 2022-12-06 | アップグレード | BTIG Research | Neutral → Buy |
| 2022-09-19 | 再開されました | Wedbush | Outperform |
| 2022-08-16 | ダウングレード | BTIG Research | Buy → Neutral |
| 2022-02-11 | 開始されました | BTIG Research | Buy |
| 2021-07-26 | 開始されました | Cowen | Outperform |
| 2021-07-26 | 開始されました | Evercore ISI | Outperform |
| 2021-07-26 | 開始されました | Jefferies | Buy |
| 2021-07-26 | 開始されました | Wedbush | Outperform |
すべてを表示
Jade Biosciences Inc (JBIO) 最新ニュース
Insider Buying: CEO Tom Frohlich Acquires Shares in Jade Biosciences Inc (JBIO) - GuruFocus
Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Jade Biosciences, Inc. Completes Reverse Merger, Launches Nasdaq Trading as JBIO, and Secures $300 Million Financing - Nasdaq
Jade Biosciences Secures Massive $300M Funding After Nasdaq Debut, First Clinical Trial Set for 2025 - Stock Titan
Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference - The Manila Times
Stifel Nicolaus Initiates Coverage on Jade Biosciences With Buy Rating, $19 Price Target - marketscreener.com
Stifel initiates Jade Biosciences stock with a Buy, $19 target By Investing.com - Investing.com India
Stifel initiates Jade Biosciences stock with a Buy, $19 target - Investing.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE and PFIE on Behalf of Shareholders - marketscreener.com
Aerovate Therapeutics, Inc. Announces Board Changes - marketscreener.com
TD Cowen starts Jade Biosciences coverage with Buy rating By Investing.com - Investing.com Nigeria
TD Cowen Initiates Coverage on Jade Biosciences With Buy Rating - marketscreener.com
TD Cowen starts Jade Biosciences coverage with Buy rating - Investing.com
Aerovate Therapeutics Completes Merger with Jade Biosciences - TipRanks
Aerovate Therapeutics Announces Range of Expected Cash Dividend - marketscreener.com
RTW Biotech Opportunities’ Jade Biosciences merges with Aerovate Therapeutics - QuotedData
Jade Biosciences closes merger with Aerovate Therapeutics - Business in Vancouver
Jade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously ... - Bluefield Daily Telegraph
Jade Biosciences Completes Closing of Merger with Aerovate - GlobeNewswire
Aerovate Therapeutics, Inc. SEC 10-Q Report - TradingView
Aerovate (AVTE) Approves 1-for-35 Reverse Stock Split Amid Merge - GuruFocus
Aerovate Therapeutics stockholders approve proposed merger with Jade Biosciences - TipRanks
Aerovate Therapeutics Stockholders Approve Proposed Merger With Jade Biosciences And All Related Proposals - marketscreener.com
Aerovate approves reverse split ahead of Jade merger - Investing.com
Aerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade Biosciences - The Malaysian Reserve
Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences - PR Newswire
Aerovate Therapeutics Inc. (AVTE) reports earnings - qz.com
AEROVATE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Aerovate Therapeutics, Inc.AVTE - Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE, BMTX, PFIE, ALTR on Behalf of Shareholders - ACCESS Newswire
Jade Biosciences to Participate in TD Cowen’s 45th Annual - GlobeNewswire
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The MergerIPG, VTS, AVTE, MHLD - The Victoria Advocate
AVTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aerovate Therapeutics, Inc. Is Fair to Shareholders - Business Wire
Borealis Biosciences Appoints Christian Hordo as CEO and Expands Series A Financing - Business Wire
Jade Biosciences to Participate in Upcoming Investor Conferences - GlobeNewswire
How Fairmount’s Paragon incubator steered two more companies to NASDAQ - biocentury.com
Paragon spinout Jade casts reverse merger spell with Aerovate - Fierce Biotech
Paragon launches another company in hot PD-1xVEGF space that goes straight to reverse merger - Endpoints News
Chinook alums reunite following exit to Novartis; The first board appointment for Recursion’s Chris Gibson - Endpoints News
Jade Biosciences Appoints Tom Frohlich as Chief Executive Officer and Hetal Kocinsky as Chief Medical Officer; Forms Board of Directors and Expands Financing to $95 Million - PR Newswire
RTW backs Jade Biosciences - QuotedData
Jade Biosciences - The Pharma Letter
Biotech Financing Roundup: Jade Bio’s Launch, Brenig’s Debut, Confo’s Cash & More - MedCity News
Chutes & Ladders—Takeda taps internal leader as head of US oncology business - Fierce Biotech
Jade Biosciences Launches with $80 Million to Develop Transformative Therapies for Autoimmune Diseases - PR Newswire
Aerovate scraps late-stage study of lung disorder drug - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
AVTEAerovate Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Jade Biosciences Inc Stock Price Today | NASDAQ: JBIO Live - Investing.com
Jade Biosciences Inc (JBIO) 財務データ
Jade Biosciences Inc (JBIO) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
0.00%
0.96%
大文字化:
|
ボリューム (24 時間):